Cite
MLA Citation
Ralf Gutzmer et al.. “Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.” Lancet, vol. 395, no. 10240, 2020, pp. 1835–1844. http://access.bl.uk/ark:/81055/vdc_100104119673.0x000055